Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Depreciation & Amortization (CF): 2009-2024

Historic Depreciation & Amortization (CF) for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to $1.2 million.

  • Ironwood Pharmaceuticals' Depreciation & Amortization (CF) fell 6.31% to $475,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year decrease of 6.48%. This contributed to the annual value of $1.2 million for FY2024, which is negligibly% changed negligibly from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Depreciation & Amortization (CF) of $1.2 million as of FY2024, which was down 0.00% from $1.2 million recorded in FY2023.
  • In the past 5 years, Ironwood Pharmaceuticals' Depreciation & Amortization (CF) ranged from a high of $2.3 million in FY2020 and a low of $1.2 million during FY2023.
  • For the 3-year period, Ironwood Pharmaceuticals' Depreciation & Amortization (CF) averaged around $1.3 million, with its median value being $1.2 million (2024).
  • Data for Ironwood Pharmaceuticals' Depreciation & Amortization (CF) shows a maximum YoY slumped of 58.93% (in 2020) over the last 5 years.
  • Ironwood Pharmaceuticals' Depreciation & Amortization (CF) (Yearly) stood at $2.3 million in 2020, then tumbled by 34.78% to $1.5 million in 2021, then fell by 6.67% to $1.4 million in 2022, then decreased by 14.29% to $1.2 million in 2023, then remained steady at $1.2 million in 2024.